Consano Bio Closes Oversubscribed Financing Past $15M Target for Sciatica Biologic

Consano Bio has completed an oversubscribed private financing above its $15M target, capital it will use to finish an ongoing Phase 1 study of C-1101, an investigational platelet- and plasma-derived multi-protein biologic for chronic painful lumbosacral radiculopathy — commonly called chronic sciatica.

The Burlington, Massachusetts company said the October 5 transaction drew a syndicate of accredited private investors and brought total capital raised to more than $45M since it was founded in 2023. Consano Bio did not disclose an exact amount above the target, name any investor, assign a formal round label or provide a valuation. With no lead investor identified and no Series A or Series B designation attached, the defensible description is a private financing rather than a stage inferred from its size.

The proceeds have a defined job. Consano Bio says the money will complete the ongoing Phase 1 study of C-1101 and support additional scientific and intellectual-property work around the program and other assets. Enrollment is expected to finish in early 2027, with clinical data arriving in the first half of the year.

C-1101 is designed as an epidural injection that places cytokines, growth factors and matrix proteins near an injured nerve, with the aim of modulating inflammation and encouraging localized cellular and tissue repair. That places the program against existing care, which Consano Bio characterizes as providing temporary or incomplete symptom relief. The company is pursuing a disease-modifying claim — an ambition that raises both the potential value of a positive result and the burden of proof required to earn one.

The C-1101-101 study is a randomized, controlled, double-blind, dose-escalation Phase 1 trial designed to enroll 24 adults across three sequential cohorts in Australia and the United States. Each participant receives a single epidural injection of C-1101 or saline. Safety and tolerability are the primary early obligations, with additional assessments of pain, physical function and sleep quality.

Regulatory momentum has accompanied the raise. The U.S. Food and Drug Administration cleared the company's investigational new drug application in July 2026, allowing the study to expand into U.S. sites, and granted Fast Track designation for C-1101 in August. Fast Track can facilitate development and expedite parts of review for drugs addressing serious conditions and unmet needs, but it does not establish that a therapy works or replace the clinical evidence required for approval.

The preclinical record behind the financing cuts both ways. A peer-reviewed paper published in September 2026 reported that C-1101 reduced allodynia, a pain-sensitivity measure, in a mouse model of peripheral neuropathy, and cell studies showed biological activity relevant to inflammation, repair and cell signaling. The same paper reported a mixed inflammatory response in cultured cells — increases in both pro-inflammatory and anti-inflammatory cytokines — and stated that the mechanism requires further investigation. Consano Bio funded the work, company employees were among the authors, and the funder participated in study design and writing, though the paper states the company was not directly involved in data collection, analysis or interpretation.